The present disclosure provides compounds, compositions containing such compounds, and methods of designing, developing, producing and preparing compounds represented by general Formula (I), including pharmaceutically acceptable salts thereof or a synthetic intermediate thereof: ##STR00001##
The compounds act as MEK inhibitors and are capable of displaying one or more beneficial therapeutic effects, including treating cancer.

The present invention relates to a compound that binds to and modulates the activity of sortilin, wherein the compound has a blood-to-brain K.sub.puu greater than 0.1. The compounds are capable of crossing the blood brain barrier and are suitable for use in the treatment of a disease of the central nervous system. The invention also relates to compounds of formula (I), which are modulators of sortilin activity, pharmaceutical compositions comprising these compounds and the use of these compounds in the treatment or prevention of medical conditions where modulation of sortilin activity is beneficial.

##STR00001##

The present disclosure provides compounds, compositions containing such compounds, and methods of designing, developing, producing and preparing compounds represented by general Formula (I), including pharmaceutically acceptable salts thereof or a synthetic intermediate thereof:

##STR00001##

The compounds act as MEK inhibitors and are capable of displaying one or more beneficial therapeutic effects, including treating cancer.

The present disclosure provides compounds, compositions containing such compounds, and methods of designing, developing, producing and preparing compounds represented by general Formula (I), including pharmaceutically acceptable salts thereof or a synthetic intermediate thereof:

##STR00001##

The compounds act as MEK inhibitors and are capable of displaying one or more beneficial therapeutic effects, including treating cancer.